Evidence map›Paper›PMID 35419001›Full record

ArticleFrontiers in immunology2022

Nevien Ismail, Subir Karmakar, Parna Bhattacharya, Telly Sepahpour, Kazuyo Takeda, Shinjiro Hamano, Greg Matlashewski, Abhay R Satoskar, Sreenivas Gannavaram, Ranadhir Dey and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Live attenuated-nonpathogenicFrontiers in microbiology · 2024
    Review
  10. Review
  11. Article
  12. The History of Live AttenuatedPathogens (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Nevien IsmailDivision of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD, United States.
Subir KarmakarDivision of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD, United States.
Parna BhattacharyaDivision of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD, United States.
Telly SepahpourDivision of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD, United States.
Kazuyo TakedaLaboratory of Clinical Hematology, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD, United States.
Shinjiro HamanoDepartment of Parasitology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.
Greg MatlashewskiDepartment of Microbiology and Immunology, McGill University, Montreal, QC, Canada.
Abhay R SatoskarDepartment of Pathology and Microbiology, Ohio State University, Columbus, OH, United States.
Sreenivas GannavaramDivision of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD, United States.
Ranadhir DeyDivision of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD, United States.
Hira L NakhasiDivision of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD, United States.
Center for Biologics Evaluation and Research · USMcGill University · CANagasaki University · JPThe Ohio State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leishmaniasis is a vector-borne parasitic disease transmitted through the bite of a sand fly with no available vaccine for humans. Recently, we have developed a live attenuated

Indexed as

Leishmania majorLeishmaniasis VaccinesParasitesAnimalsImmunityInterferon-gammaMemory T CellsMiceSkinTrimethoprim, Sulfamethoxazole Drug CombinationInterferon-gammaLeishmaniasis VaccinesTrimethoprim, Sulfamethoxazole Drug CombinationcytokinesGranzyme BLeishmania majorleishmanizationlive attenuated Leishmania vaccinetissue resident memory T cells

Identifiers

PMID35419001
PMCPMC8996177
OpenAlexW4221062434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.